Ortho licenses Agen's D-dimer heart attack test
This article was originally published in Clinica
Executive Summary
Australian company Agen has licensed its D-dimer blood clot tests to Ortho Diagnostic Systems on a non-exclusive basis. The test is based on the DD3B6/22 monoclonal antibody which, like the Washington soluble fibrinogen test, recognises the signs of clot degradation. Announcing the deal just one day after the ACC meeting, Agen's managing director, Roman Zwolenski, said: "The worldwide D-dimer testing market is estimated to be worth US$45 million, and growing significantly." This is Agen's second licence agreement since the European Patent Office upheld its D-dimer patent. Agen is collaborating on the development of an instrument for rapid heart attack testing with US company Source Scientific.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.